COMP <GO>
ALNY vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ALNY 2
— LLY 13
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $165.00 (-5.17%) • MKT CAP: $23.28B
balance-sheet
3.16
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 83.64% | -1.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | 32.36% | -11.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | 36.4x | +5.98 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | 2.30% | -0.30 | LLY | /fcf-yield <GO> |
| Operating Margin | 13.50% | 40.21% | -26.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 31.90% | -23.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | 45.51% | +19.69 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.16 | 9.29 | -6.13 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.1 | 77.9 | -55.83 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.51 | +0.49 | ALNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 26.3x | +36.05 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.28B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | LLY REV | ALNY GROSS % | LLY GROSS % | ALNY FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $65.18B | 81.8% | 83.0% | $465.4M | $16.81B |
| FY 2024 | $2.25B | $45.04B | 86.4% | 81.3% | -$42.6M | $8.82B |
| FY 2023 | $1.83B | $34.12B | 44.0% | 79.3% | $21.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
LLY // BETA 0.51